Cargando…
Targeting BRAF and RAS in Colorectal Cancer
SIMPLE SUMMARY: In colorectal cancer, mutations of the KRAS and BRAF genes are quite common and can contribute to the activation of cell signaling pathways that lead to cell proliferation and differentiation. These processes promote cancer growth, and in some cases, they may cause cells to develop r...
Autores principales: | Bellio, Helene, Fumet, Jean David, Ghiringhelli, Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124706/ https://www.ncbi.nlm.nih.gov/pubmed/34063682 http://dx.doi.org/10.3390/cancers13092201 |
Ejemplares similares
-
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
por: Ghiringhelli, François, et al.
Publicado: (2019) -
Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Bellio, Hélène, et al.
Publicado: (2021) -
Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
por: Fumet, Jean-David, et al.
Publicado: (2020) -
Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
por: Fumet, Jean-David, et al.
Publicado: (2017) -
Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
por: Guarini, Chiara, et al.
Publicado: (2021)